Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares OutstandingShares Outstanding
Ratios

Bioregenx (BRGX) Cost of Revenue (2023 - 2025)

Bioregenx has reported Cost of Revenue over the past 3 years, most recently at $66866.0 for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 51.46% year-over-year to $66866.0; the TTM value through Dec 2025 reached $350854.0, down 48.53%, while the annual FY2025 figure was $350855.0, 48.53% down from the prior year.
  • Cost of Revenue for Q4 2025 was $66866.0 at Bioregenx, down from $81358.0 in the prior quarter.
  • Over five years, Cost of Revenue peaked at $311694.0 in Q1 2023 and troughed at $66866.0 in Q4 2025.
  • A 3-year average of $177710.5 and a median of $151571.0 in 2024 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: dropped 0.31% in 2024 and later plummeted 64.6% in 2025.
  • Year by year, Cost of Revenue stood at $299983.0 in 2023, then tumbled by 54.08% to $137752.0 in 2024, then plummeted by 51.46% to $66866.0 in 2025.
  • Business Quant data shows Cost of Revenue for BRGX at $66866.0 in Q4 2025, $81358.0 in Q3 2025, and $93514.0 in Q2 2025.